Companies /Healthcare

Design Therapeutics Inc

NASDAQ: DSGN Biotechnology
$9.91
▼ $0.56 (−5.35%) today
Markets open · 3:35pm ET

DSGN at a Glance

Valuation
Market cap
$670.5M
Profitability
Revenue (TTM)
$33,000
EPS (TTM)
$-1.20
Price
52-week range
$7 – $17
Street target
$21.57

Headquartered in Carlsbad, CA Fiscal year ends December NASDAQ: DSGN designtx.com

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies for serious degenerative genetic diseases. Its therapies are based on the company's GeneTAC® (gene targeted chimera) small-molecule platform. GeneTAC® molecules are designed to either increase or decrease expression of a specific disease-causing gene, addressing the underlying cause of disease. The clinical pipeline has three programs. DT-216P2 for Friedreich ataxia is in the Phase 1/2 RESTORE-FA multiple ascending dose trial, with a registrational plan update expected in Q4 2026 and 12-week data in Q1 2027. DT-818 for myotonic dystrophy type-1 is in a Phase 1 MAD trial and is designed to selectively reduce transcription of the mutant DMPK allele. DT-168 for Fuchs endothelial corneal dystrophy is in a Phase 2 biomarker trial. The company is also advancing a preclinical Huntington's disease program and discovery efforts in other genomic medicines. It has no product revenue and funds operations from its cash and investment securities. Updated

Latest Activity

DSGNDesign Therapeutics
Q3 2026
EPS
-$0.32
est -$0.35+7.6%
Revenue
$0K

The loss came in narrower than expected, but the number that matters for a $665 million clinical-stage biotech is $208.6 million in cash and securities against roughly $22 million of quarterly operating spend. Management says a registrational plan update for its lead Friedreich ataxia program lands this quarter, with 12-week RESTORE-FA data due in early 2027.

Quarterly EPS — reported vs estimate

DSGN Coverage

Frequently Asked Questions

What does Design Therapeutics do?

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies for serious degenerative genetic diseases. Its therapies are based on the company's GeneTAC® (gene targeted chimera) small-molecule platform.

What is the DSGN stock price target?

The Wall Street consensus 12-month price target for DSGN is $21.57.